Skip to main content



Professor Carl Borrebaeck received the first chair as professor of Immunotechnology in Scandinavia 1989, when the Department was inaugurated. His main research interests are cancer proteomics, for early detection and prognosis, antibody engineering, for the generation of human therapeutic antibodies and mechanisms and prediction of allergy.


Professor Borrebaeck spent a sabbatical year at the Oklahoma Medical Research Foundation 1996-97 and did his post-doctoral training at the University of California in Davis. Today Professor Borrebaeck is scientific director of CREATE Health a center for Translational Cancer Research at Lund University, where the focus is to work with complex clinical problems using advanced technologies.


He is a permanent member of the Royal Swedish Academy of Engineering Sciences. He received the AKZO Nobel Science Award 2009, for his contributions to cancer proteomics and antibody-based therapy, the Research!Sweden Award 2012 for his medical research of value for patients and health organizations, and the Royal Academy of Engineering Sciences Gold Medal 2012 for outstanding contributions to biomedical science. 2017 he was awarded as Biotech Builder of the year.

Spin-out companies

Professor Borrebaeck´s research has resulted in several spin-out companies, such as BioInvent International AB, Alligator Bioscience AB, Immunovia AB and SenzaGen AB, focusing on different aspects of diagnosis or therapy of complex diseases. The most recent company started by Professor Borrebaeck is PainDrainer AB, an eHealth company developing a mobile medical device that will allow patients with chronic pain to manage their pain and increase the quality of life.

Carl Borrebaeck. Portrait.

Senior Professor Carl Borrebaeck
+46-46 222 96 13

Medicon Village
Building 406
Scheelevägen 2
223 63 LUND

Page Manager: | 2021-03-19